{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:20:22Z","timestamp":1788931222542,"version":"build-2803163510"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This review article series on water and electrolyte disorders is based on the \u2018Electrolyte Winter Seminar\u2019 held annually for young nephrologists in Japan. This is the third article in this series that focuses on water and electrolyte disturbances caused by novel pharmacological agents for kidney disease and cancer. The advent of novel pharmacological agents in cardiorenal medicine and oncology has introduced both therapeutic benefits and challenges in managing medication-induced water and electrolyte disturbances. These medications, including sodium\u2013glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (ns-MRAs), and immune checkpoint inhibitors (ICIs), significantly impact water and electrolyte homeostasis. SGLT2 inhibitors used widely in diabetes mellitus, heart failure, and chronic kidney disease mitigate hyperkalemia and hypomagnesemia but increase the risk of hypernatremia in patients on fluid restriction. Conversely, they are beneficial for managing hyponatremia in the syndrome of inappropriate antidiuresis (SIAD). ns-MRAs, prescribed for diabetic kidney disease, exhibit a high risk of hyperkalemia, particularly when combined with renin\u2013angiotensin system inhibitors. ICIs, a breakthrough in oncology, frequently induce hyponatremia through immune-related adverse events, such as hypophysitis and non-immune-related adverse events like SIAD. Understanding the pathophysiology of these disturbances and implementing timely interventions, including hormone replacement and water and electrolyte management, is critical for optimizing treatment outcomes.<\/jats:p>","DOI":"10.1007\/s10157-025-02635-6","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T05:05:02Z","timestamp":1739336702000},"page":"521-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Maho","family":"Terashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-5347","authenticated-orcid":false,"given":"Masahiko","family":"Yazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoka","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Electrolyte Winter Seminar Collaborative Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Fujimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyogo","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Monkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Nagahama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ryuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"1","key":"2635_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1172\/jci116972","volume":"93","author":"Y Kanai","year":"1994","unstructured":"Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93(1):397\u2013404. https:\/\/doi.org\/10.1172\/jci116972.","journal-title":"J Clin Invest"},{"issue":"2","key":"2635_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2215\/cjn.09380822","volume":"18","author":"BF Palmer","year":"2023","unstructured":"Palmer BF, Clegg DJ. Kidney-protective effects of SGLT2 inhibitors. Clin J Am Soc Nephrol. 2023;18(2):279\u201389. https:\/\/doi.org\/10.2215\/cjn.09380822.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2635_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1515920.","journal-title":"N Engl J Med"},{"issue":"7","key":"2635_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"issue":"24","key":"2635_CR5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"15","key":"2635_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"2635_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"23","key":"2635_CR8","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/circulationaha.124.069568","volume":"149","author":"SM Patel","year":"2024","unstructured":"Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, et al. Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis. Circulation. 2024;149(23):1789\u2013801. https:\/\/doi.org\/10.1161\/circulationaha.124.069568.","journal-title":"Circulation"},{"issue":"6","key":"2635_CR9","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.34067\/KID.0001172021","volume":"2","author":"AY Meraz-Mu\u00f1oz","year":"2021","unstructured":"Meraz-Mu\u00f1oz AY, Weinstein J, Wald R. eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined. Kidney360. 2021;2(6):1042\u20137.","journal-title":"Kidney360"},{"key":"2635_CR10","doi-asserted-by":"publisher","first-page":"110239","DOI":"10.1016\/j.diabres.2023.110239","volume":"196","author":"C Charlwood","year":"2023","unstructured":"Charlwood C, Chudasama J, Darling AL, Logan Ellis H, Whyte MB. Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: a meta-analysis. Diabetes Res Clin Pract. 2023;196:110239. https:\/\/doi.org\/10.1016\/j.diabres.2023.110239.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"2635_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2215\/cjn.0000000000000205","volume":"18","author":"X Luo","year":"2023","unstructured":"Luo X, Xu J, Zhou S, Xue C, Chen Z, Mao Z. Influence of SGLT2i and RAASi and their combination on risk of hyperkalemia in DKD: a network meta-analysis. Clin J Am Soc Nephrol. 2023;18(8):1019\u201330. https:\/\/doi.org\/10.2215\/cjn.0000000000000205.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2635_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2215\/cjn.0000000000000300","volume":"19","author":"BF Palmer","year":"2024","unstructured":"Palmer BF, Clegg DJ. SGLT2 inhibition and kidney potassium homeostasis. Clin J Am Soc Nephrol. 2024;19(3):399\u2013405. https:\/\/doi.org\/10.2215\/cjn.0000000000000300.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2635_CR13","doi-asserted-by":"publisher","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","volume":"319","author":"A Onishi","year":"2020","unstructured":"Onishi A, Fu Y, Patel R, Darshi M, Crespo-Masip M, Huang W, et al. A role for tubular Na(+)\/H(+) exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am J Physiol Renal Physiol. 2020;319(4):F712\u201328. https:\/\/doi.org\/10.1152\/ajprenal.00264.2020.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"2635_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2337\/dc20-2604","volume":"44","author":"RA Scholtes","year":"2021","unstructured":"Scholtes RA, Muskiet MHA, van Baar MJB, Hesp AC, Greasley PJ, Karlsson C, et al. Natriuretic effect of two weeks of Dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care. 2021;44(2):440\u20137. https:\/\/doi.org\/10.2337\/dc20-2604.","journal-title":"Diabetes Care"},{"key":"2635_CR15","doi-asserted-by":"publisher","first-page":"738848","DOI":"10.3389\/fendo.2021.738848","volume":"12","author":"S Puglisi","year":"2021","unstructured":"Puglisi S, Rossini A, Poli R, Dughera F, Pia A, Terzolo M, et al. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front Endocrinol (Lausanne). 2021;12:738848. https:\/\/doi.org\/10.3389\/fendo.2021.738848.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2635_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/ijms20030629","volume":"20","author":"TM Ansary","year":"2019","unstructured":"Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci. 2019;20(3):629. https:\/\/doi.org\/10.3390\/ijms20030629.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2635_CR17","doi-asserted-by":"publisher","first-page":"19603","DOI":"10.1038\/s41598-022-24280-9","volume":"12","author":"W Manosroi","year":"2022","unstructured":"Manosroi W, Danpanichkul P, Atthakomol P. Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis. Sci Rep. 2022;12(1):19603. https:\/\/doi.org\/10.1038\/s41598-022-24280-9.","journal-title":"Sci Rep"},{"issue":"1","key":"2635_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1681\/asn.2021121544","volume":"34","author":"JP Bahena-Lopez","year":"2023","unstructured":"Bahena-Lopez JP, Rojas-Vega L, Ch\u00e1vez-Canales M, Bazua-Valenti S, Bautista-P\u00e9rez R, Lee JH, et al. Glucose\/Fructose delivery to the distal nephron activates the sodium-chloride cotransporter via the calcium-sensing receptor. J Am Soc Nephrol. 2023;34(1):55\u201372. https:\/\/doi.org\/10.1681\/asn.2021121544.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2635_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13730-023-00790-x","volume":"13","author":"J Sugiyama","year":"2024","unstructured":"Sugiyama J, Ryuge A, Mitsubayashi K, Ito M, Matsumoto N, Takeuchi R, et al. Dapagliflozin induced hypernatremia via osmotic diuresis: a case report. CEN case reports. 2024;13(1):9\u201313. https:\/\/doi.org\/10.1007\/s13730-023-00790-x.","journal-title":"CEN case reports"},{"issue":"1","key":"2635_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40800-017-0058-8","volume":"4","author":"G Gelbenegger","year":"2017","unstructured":"Gelbenegger G, Buchtele N, Schoergenhofer C, Roeggla M, Schwameis M. Severe hypernatraemic dehydration and unconsciousness in a care-dependent inpatient treated with Empagliflozin. Drug Saf Case Rep. 2017;4(1):17. https:\/\/doi.org\/10.1007\/s40800-017-0058-8.","journal-title":"Drug Saf Case Rep"},{"issue":"3","key":"2635_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jphs.2021.07.006","volume":"147","author":"K Kitada","year":"2021","unstructured":"Kitada K, Kidoguchi S, Nakano D, Nishiyama A. Sodium\/glucose cotransporter 2 and renoprotection: From the perspective of energy regulation and water conservation. J Pharmacol Sci. 2021;147(3):245\u201350. https:\/\/doi.org\/10.1016\/j.jphs.2021.07.006.","journal-title":"J Pharmacol Sci"},{"issue":"3","key":"2635_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1681\/asn.2019090944","volume":"31","author":"J Refardt","year":"2020","unstructured":"Refardt J, Imber C, Sailer CO, Jeanloz N, Potasso L, Kutz A, et al. A randomized trial of Empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis. J Am Soc Nephrol. 2020;31(3):615\u201324. https:\/\/doi.org\/10.1681\/asn.2019090944.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2635_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1681\/asn.2022050623","volume":"34","author":"J Refardt","year":"2023","unstructured":"Refardt J, Imber C, Nobbenhuis R, Sailer CO, Haslbauer A, Monnerat S, et al. Treatment effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial. J Am Soc Nephrol. 2023;34(2):322\u201332. https:\/\/doi.org\/10.1681\/asn.2022050623.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2635_CR24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1053\/j.ajkd.2023.11.006","volume":"83","author":"CV Shah","year":"2024","unstructured":"Shah CV, Sparks MA, Lee CT. Sodium\/glucose cotransporter 2 inhibitors and magnesium homeostasis: a review. Am J Kidney Dis. 2024;83(5):648\u201358. https:\/\/doi.org\/10.1053\/j.ajkd.2023.11.006.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2635_CR25","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/ndt\/gfy119","volume":"34","author":"T Oka","year":"2019","unstructured":"Oka T, Hamano T, Sakaguchi Y, Yamaguchi S, Kubota K, Senda M, et al. Proteinuria-associated renal magnesium wasting leads to hypomagnesemia: a common electrolyte abnormality in chronic kidney disease. Nephrol Dial Transplant. 2019;34(7):1154\u201362. https:\/\/doi.org\/10.1093\/ndt\/gfy119.","journal-title":"Nephrol Dial Transplant"},{"key":"2635_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejim.2024.10.024","volume":"131","author":"R Sato","year":"2025","unstructured":"Sato R, Koziolek MJ, von Haehling S. Translating evidence into practice: managing electrolyte imbalances and iron deficiency in heart failure. Eur J Intern Med. 2025;131:15\u201326. https:\/\/doi.org\/10.1016\/j.ejim.2024.10.024.","journal-title":"Eur J Intern Med"},{"issue":"5","key":"2635_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10157-022-02182-4","volume":"26","author":"Y Sakaguchi","year":"2022","unstructured":"Sakaguchi Y. The emerging role of magnesium in CKD. Clin Exp Nephrol. 2022;26(5):379\u201384. https:\/\/doi.org\/10.1007\/s10157-022-02182-4.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"2635_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3177\/jnsv.68.270","volume":"68","author":"Y Ashitomi","year":"2022","unstructured":"Ashitomi Y, Konta T, Motoi F, Watanabe M, Kayama T, Ueno Y. Association between serum magnesium levels and mortality in a community-based population: The Yamagata (Takahata) Study. J Nutr Sci Vitaminol (Tokyo). 2022;68(4):270\u20135. https:\/\/doi.org\/10.3177\/jnsv.68.270.","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"issue":"3","key":"2635_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.34067\/KID.0006672021","volume":"3","author":"J Zhang","year":"2022","unstructured":"Zhang J, Huan Y, Leibensperger M, Seo B, Song Y. Comparative effects of sodium-glucose cotransporter 2 inhibitors on serum electrolyte levels in patients with type 2 diabetes a pairwise and network meta-analysis of randomized controlled trials. Kidney. 2022;3(3):477\u201387.","journal-title":"Kidney"},{"key":"2635_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-024-02590-8","author":"K Osawa","year":"2024","unstructured":"Osawa K, Ohya M, Yamamoto S, Nakashima Y, Tanaka Y, Yamano Y, et al. SGLT2 inhibitors increase low serum magnesium levels in patients with chronic kidney disease immediately after treatment. Clin Exp Nephrol. 2024. https:\/\/doi.org\/10.1007\/s10157-024-02590-8.","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"2635_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.xkme.2020.01.010","volume":"2","author":"EC Ray","year":"2020","unstructured":"Ray EC, Boyd-Shiwarski CR, Liu P, Novacic D, Cassiman D. SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients. Kidney Med. 2020;2(3):359\u201364. https:\/\/doi.org\/10.1016\/j.xkme.2020.01.010.","journal-title":"Kidney Med"},{"key":"2635_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.12.018","author":"CV Shah","year":"2024","unstructured":"Shah CV. Sotagliflozin in refractory hypomagnesemia. Kidney Int Rep. 2024. https:\/\/doi.org\/10.1016\/j.ekir.2024.12.018.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"2635_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.247","volume":"4","author":"KM Wang","year":"2021","unstructured":"Wang KM, Li J, Bhalla V, Jardine MJ, Neal B, de Zeeuw D, et al. Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program. Endocrinol Diabetes Metab. 2021;4(3): e00247. https:\/\/doi.org\/10.1002\/edm2.247.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"5","key":"2635_CR34","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","volume":"80","author":"M Epstein","year":"2022","unstructured":"Epstein M, Kovesdy CP, Clase CM, Sood MM, Pecoits-Filho R. Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms. Am J Kidney Dis. 2022;80(5):658\u201366. https:\/\/doi.org\/10.1053\/j.ajkd.2022.04.016.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2635_CR35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","volume":"42","author":"A Nishiyama","year":"2019","unstructured":"Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res. 2019;42(3):293\u2013300. https:\/\/doi.org\/10.1038\/s41440-018-0158-6.","journal-title":"Hypertens Res"},{"issue":"8","key":"2635_CR36","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.34067\/KID.0000952022","volume":"3","author":"SJ Leon","year":"2022","unstructured":"Leon SJ, Tangri N. Balancing hyperkalemia risks with clinical benefits of renin-angiotensin-aldosterone inhibitors\/mineralocorticoid recesptor antagonists blockade: at\u2019s apples and oranges. Kidney360. 2022;3(8):1442\u20134.","journal-title":"Kidney360"},{"issue":"23","key":"2635_CR37","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"issue":"24","key":"2635_CR38","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"issue":"6","key":"2635_CR39","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777.","journal-title":"Eur Heart J"},{"issue":"31","key":"2635_CR40","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363. https:\/\/doi.org\/10.1093\/eurheartj\/eht187.","journal-title":"Eur Heart J"},{"issue":"2","key":"2635_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","volume":"16","author":"R Agarwal","year":"2023","unstructured":"Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, et al. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2023;16(2):293\u2013302. https:\/\/doi.org\/10.1093\/ckj\/sfac234.","journal-title":"Clin Kidney J"},{"issue":"10208","key":"2635_CR42","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/s0140-6736(19)32135-x","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540\u201350. https:\/\/doi.org\/10.1016\/s0140-6736(19)32135-x.","journal-title":"Lancet"},{"issue":"2","key":"2635_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/fcp.12170","volume":"30","author":"S Lentini","year":"2016","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016;30(2):172\u201384. https:\/\/doi.org\/10.1111\/fcp.12170.","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"2635_CR44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-019-00820-x","volume":"59","author":"N Snelder","year":"2020","unstructured":"Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, et al. Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet. 2020;59(3):359\u201370. https:\/\/doi.org\/10.1007\/s40262-019-00820-x.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2635_CR45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","volume":"29","author":"P Gardiner","year":"1989","unstructured":"Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989;29(4):342\u20137. https:\/\/doi.org\/10.1002\/j.1552-4604.1989.tb03339.x.","journal-title":"J Clin Pharmacol"},{"key":"2635_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271\u2013305. https:\/\/doi.org\/10.1007\/164_2016_76.","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"2635_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/fjc.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69\u201378. https:\/\/doi.org\/10.1097\/fjc.0000000000000091.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"2635_CR48","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u201317. https:\/\/doi.org\/10.1056\/nejm199909023411001.","journal-title":"N Engl J Med"},{"issue":"6","key":"2635_CR49","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543\u201351. https:\/\/doi.org\/10.1056\/NEJMoa040135.","journal-title":"N Engl J Med"},{"issue":"6","key":"2635_CR50","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","volume":"42","author":"J Bauersachs","year":"2021","unstructured":"Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021;42(6):681\u20133. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1012.","journal-title":"Eur Heart J"},{"issue":"6","key":"2635_CR51","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/circulationaha.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024;149(6):450\u201362. https:\/\/doi.org\/10.1161\/circulationaha.123.067584.","journal-title":"Circulation"},{"issue":"22","key":"2635_CR52","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387(22):2021\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2210639.","journal-title":"N Engl J Med"},{"key":"2635_CR53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409183","author":"WG Herrington","year":"2024","unstructured":"Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, et al. Long-term effects of Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2409183.","journal-title":"N Engl J Med"},{"issue":"1","key":"2635_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","volume":"7","author":"P Rossing","year":"2022","unstructured":"Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36\u201345. https:\/\/doi.org\/10.1016\/j.ekir.2021.10.008.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2635_CR55","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","volume":"103","author":"GL Bakris","year":"2023","unstructured":"Bakris GL, Ruilope LM, Anker SD, Filippatos G, Pitt B, Rossing P, et al. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023;103(1):196\u2013206. https:\/\/doi.org\/10.1016\/j.kint.2022.08.040.","journal-title":"Kidney Int"},{"issue":"4","key":"2635_CR56","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00392-021-01853-8","volume":"111","author":"P Martens","year":"2022","unstructured":"Martens P, Ferreira JP, Vincent J, Abreu P, Busselen M, Mullens W, et al. Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial. Clin Res Cardiol. 2022;111(4):380\u201392. https:\/\/doi.org\/10.1007\/s00392-021-01853-8.","journal-title":"Clin Res Cardiol"},{"key":"2635_CR57","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000493246","volume":"52","author":"G Liamis","year":"2019","unstructured":"Liamis G, Megapanou E, Elisaf M, Milionis H. Hyponatremia-inducing drugs. Front Horm Res. 2019;52:167\u201377. https:\/\/doi.org\/10.1159\/000493246.","journal-title":"Front Horm Res"},{"issue":"17\u201318","key":"2635_CR58","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00508-022-02040-z","volume":"134","author":"I Velat","year":"2022","unstructured":"Velat I, Bu\u0161i\u0107 \u017d, \u010culi\u0107 V. Clinical predictors of hyponatremia in patients with heart failure according to severity of chronic kidney disease. Wien Klin Wochenschr. 2022;134(17\u201318):636\u201345. https:\/\/doi.org\/10.1007\/s00508-022-02040-z.","journal-title":"Wien Klin Wochenschr"},{"issue":"6","key":"2635_CR59","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/jcpt.13243","volume":"45","author":"Y Feng","year":"2020","unstructured":"Feng Y, Yin Y, Deng R, Li H. Renal safety and efficacy of angiotensin receptor-neprilysin inhibitor: A meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2020;45(6):1235\u201343. https:\/\/doi.org\/10.1111\/jcpt.13243.","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"2635_CR60","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"issue":"5","key":"2635_CR61","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ejhf.232","volume":"17","author":"AA Voors","year":"2015","unstructured":"Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015;17(5):510\u20137. https:\/\/doi.org\/10.1002\/ejhf.232.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2635_CR62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","volume":"2","author":"AS Desai","year":"2017","unstructured":"Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017;2(1):79\u201385. https:\/\/doi.org\/10.1001\/jamacardio.2016.4733.","journal-title":"JAMA Cardiol"},{"key":"2635_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3454","author":"DV Nguyen","year":"2024","unstructured":"Nguyen DV, Le TN, Truong BQ, Nguyen HTT. Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis. Eur J Heart Fail. 2024. https:\/\/doi.org\/10.1002\/ejhf.3454.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2635_CR64","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):4\u2013131. https:\/\/doi.org\/10.1002\/ejhf.2333.","journal-title":"Eur J Heart Fail"},{"issue":"1157","key":"2635_CR65","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/postgradmedj-2020-139284","volume":"98","author":"SR Mohammed","year":"2022","unstructured":"Mohammed SR, Pinto Pereira LM, Hanoman H, Teelucksingh S. Chronic asymptomatic hyponatraemia following angiotensin receptor blocker-neprilysin inhibitor (ARNi) therapy: a case report. Postgrad Med J. 2022;98(1157):165. https:\/\/doi.org\/10.1136\/postgradmedj-2020-139284.","journal-title":"Postgrad Med J"},{"issue":"5","key":"2635_CR66","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/0897190019828915","volume":"33","author":"I Fuzaylova","year":"2020","unstructured":"Fuzaylova I, Lam C, Talreja O, Makaryus AN, Ahern D, Cassagnol M. Sacubitril\/Valsartan (Entresto\u00ae)-Induced Hyponatremia. J Pharm Pract. 2020;33(5):696\u20139. https:\/\/doi.org\/10.1177\/0897190019828915.","journal-title":"J Pharm Pract"},{"issue":"4","key":"2635_CR67","doi-asserted-by":"publisher","first-page":"sfae072","DOI":"10.1093\/ckj\/sfae072","volume":"17","author":"V Ivkovi\u0107","year":"2024","unstructured":"Ivkovi\u0107 V, Bruchfeld A. Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease. Clin Kid J. 2024;17(4):sfae072. https:\/\/doi.org\/10.1093\/ckj\/sfae072.","journal-title":"Clin Kid J"},{"issue":"2","key":"2635_CR68","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","volume":"99","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Kohan DE, de Zeeuw D. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney Int. 2021;99(2):346\u20139. https:\/\/doi.org\/10.1016\/j.kint.2020.09.026.","journal-title":"Kidney Int"},{"issue":"1","key":"2635_CR69","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","volume":"15","author":"HC Pan","year":"2024","unstructured":"Pan HC, Chen JY, Chen HY, Yeh FY, Sun CY, Huang TT, et al. GLP-1 receptor agonists\u2019 impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nat Commun. 2024;15(1):5912. https:\/\/doi.org\/10.1038\/s41467-024-50199-y.","journal-title":"Nat Commun"},{"issue":"2","key":"2635_CR70","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"key":"2635_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078483","volume":"385","author":"EL Fu","year":"2024","unstructured":"Fu EL, Wexler DJ, Cromer SJ, Bykov K, Paik JM, Patorno E. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ. 2024;385: e078483. https:\/\/doi.org\/10.1136\/bmj-2023-078483.","journal-title":"BMJ"},{"issue":"2","key":"2635_CR72","doi-asserted-by":"publisher","first-page":"F231","DOI":"10.1152\/ajprenal.00432.2018","volume":"316","author":"L Tonneijck","year":"2019","unstructured":"Tonneijck L, Muskiet MHA, Blijdorp CJ, Smits MM, Twisk JW, Kramer MHH, et al. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2019;316(2):F231\u201340. https:\/\/doi.org\/10.1152\/ajprenal.00432.2018.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"2635_CR73","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","volume":"59","author":"L Tonneijck","year":"2016","unstructured":"Tonneijck L, Smits MM, Muskiet MHA, Hoekstra T, Kramer MHH, Danser AHJ, et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2016;59(7):1412\u201321. https:\/\/doi.org\/10.1007\/s00125-016-3938-z.","journal-title":"Diabetologia"},{"issue":"4","key":"2635_CR74","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.001.","journal-title":"Cancer Cell"},{"issue":"4","key":"2635_CR75","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.kint.2021.06.001","volume":"100","author":"R Wanchoo","year":"2021","unstructured":"Wanchoo R, Sakhiya V, Jhaveri KD. Immune checkpoint inhibitor-associated electrolyte disorders: query of the Food and Drug Administration Adverse Event Reporting System. Kidney Int. 2021;100(4):945\u20137. https:\/\/doi.org\/10.1016\/j.kint.2021.06.001.","journal-title":"Kidney Int"},{"issue":"12","key":"2635_CR76","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1093\/ndt\/gfaa272","volume":"36","author":"H Seethapathy","year":"2021","unstructured":"Seethapathy H, Rusibamayila N, Chute DF, Lee M, Strohbehn I, Zubiri L, et al. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant. 2021;36(12):2241\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfaa272.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2635_CR77","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.tem.2021.10.009","volume":"33","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Bianchi A, Giampietro A, Milardi D, De Marinis L, Pontecorvi A. The changing clinical spectrum of endocrine adverse events in cancer immunotherapy. Trends Endocrinol Metab. 2022;33(2):87\u2013104. https:\/\/doi.org\/10.1016\/j.tem.2021.10.009.","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"2635_CR78","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2215\/cjn.14671121","volume":"17","author":"NN Uppal","year":"2022","unstructured":"Uppal NN, Workeneh BT, Rondon-Berrios H, Jhaveri KD. Electrolyte and acid-base disorders associated with cancer immunotherapy. Clin J Am Soc Nephrol. 2022;17(6):922\u201333. https:\/\/doi.org\/10.2215\/cjn.14671121.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2635_CR79","doi-asserted-by":"publisher","first-page":"19419","DOI":"10.1038\/s41598-019-56026-5","volume":"9","author":"J Garon-Czmil","year":"2019","unstructured":"Garon-Czmil J, Petitpain N, Rouby F, Sassier M, Babai S, Y\u00e9l\u00e9h\u00e9-Okouma M, et al. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database. Sci Rep. 2019;9(1):19419. https:\/\/doi.org\/10.1038\/s41598-019-56026-5.","journal-title":"Sci Rep"},{"issue":"5","key":"2635_CR80","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/thy.2016.0597","volume":"27","author":"P Wolf","year":"2017","unstructured":"Wolf P, Beiglb\u00f6ck H, Smaijs S, Wrba T, Rasoul-Rockenschaub S, Marculescu R, et al. Hypothyroidism and hyponatremia: rather coincidence than causality. Thyroid. 2017;27(5):611\u20135. https:\/\/doi.org\/10.1089\/thy.2016.0597.","journal-title":"Thyroid"},{"issue":"1","key":"2635_CR81","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ekir.2022.10.019","volume":"8","author":"CV Shah","year":"2023","unstructured":"Shah CV, Lee HW, Clapp WL, Weiner ID. A novel form of renal tubular acidosis associated with immune checkpoint inhibitors. Kidney Int Rep. 2023;8(1):197\u2013201. https:\/\/doi.org\/10.1016\/j.ekir.2022.10.019.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"2635_CR82","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/ndt\/gfaa326","volume":"37","author":"H Izzedine","year":"2022","unstructured":"Izzedine H, Chazal T, Wanchoo R, Jhaveri KD. Immune checkpoint inhibitor-associated hypercalcaemia. Nephrol Dial Transplant. 2022;37(9):1598\u2013608. https:\/\/doi.org\/10.1093\/ndt\/gfaa326.","journal-title":"Nephrol Dial Transplant"},{"key":"2635_CR83","doi-asserted-by":"publisher","first-page":"7459268","DOI":"10.1155\/2020\/7459268","volume":"2020","author":"SS Nalluru","year":"2020","unstructured":"Nalluru SS, Piranavan P, Ning Y, Ackula H, Siddiqui AD, Trivedi N. Hypocalcemia with immune checkpoint inhibitors: the disparity among various reports. Int J Endocrinol. 2020;2020:7459268. https:\/\/doi.org\/10.1155\/2020\/7459268.","journal-title":"Int J Endocrinol"},{"issue":"1","key":"2635_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000687","volume":"8","author":"R Dadu","year":"2020","unstructured":"Dadu R, Rodgers TE, Trinh VA, Kemp EH, Cubb TD, Patel S, et al. Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. J Immunother Cancer. 2020;8(1): e000687. https:\/\/doi.org\/10.1136\/jitc-2020-000687.","journal-title":"J Immunother Cancer"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02635-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02635-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02635-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:03:41Z","timestamp":1746288221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02635-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2635"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02635-6","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this review article were in accordance with the ethical standards of the national research committee at which the studies were conducted and with the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}